SciBase lands another customer in the US
The announced partnership is with Seraly Dermatology in Pittsburgh, Pennsylvania. The customer will integrate several Nevisense systems into their skin cancer detection workflow. According to Seraly Dermatology’s website, they have a single location with a staff of 5, so the client seems to be small. Still, each customer win is a sign that the market response to Nevisense remains good and that the product continues to be well positioned.
SciBase mentioned in the press release that they are expanding to a new market. We assume Seraly Dermatology was their first customer in Pennsylvania, which could indicate that insurance coverage for Nevisense diagnostics in the state is on a positive trend. Our revenue growth estimates for Scibase assume steady customer wins, so this deal will not cause any changes to our revenue forecasts.
Login required
This content is only available for logged in users
Scibase Holding
SciBase Holding är verksamt inom medicinteknik. Koncernen är specialiserad inom hantering av cancerdiagnostik, främst inriktat mot behandling och upptäckandet av diverse melanom. Bolaget har utvecklat en elektrisk handhållen prob som analyserar mätsignalen för att upptäcka specifika förändringar i kroppens hudvävnad. Huvudkontoret ligger i Stockholm.
Read more on company pageKey Estimate Figures21.08.
| 2023 | 24e | 25e | |
|---|---|---|---|
| Omsättning | 23,2 | 29,6 | 45,8 |
| tillväxt-% | 29,94 % | 27,36 % | 54,68 % |
| EBIT (adj.) | −53,9 | −57,8 | −48,7 |
| EBIT-% | −232,04 % | −195,19 % | −106,25 % |
| EPS (adj.) | −0,50 | −0,30 | −0,22 |
| Utdelning | 0,00 | 0,00 | 0,00 |
| Direktavkastning | |||
| P/E (just.) | - | - | - |
| EV/EBITDA | - | - | - |
